Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $6.2 million.

  • Lineage Cell Therapeutics' Other Non-Current Liabilities was N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $6.2 million for FY2024, which is N/A change from last year.
  • As of FY2024, Lineage Cell Therapeutics' Other Non-Current Liabilities stood at $6.2 million, which was up 307,950.00% from $2,000 recorded in FY2022.
  • Lineage Cell Therapeutics' 5-year Other Non-Current Liabilities high stood at $6.2 million for FY2024, and its period low was $2,000 during FY2022.
  • Over the past 2 years, Lineage Cell Therapeutics' median Other Non-Current Liabilities value was $3.1 million (recorded in 2022), while the average stood at $3.1 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Non-Current Liabilities soared by 57.76% in 2020, and later crashed by 93.33% in 2022.
  • Lineage Cell Therapeutics' Other Non-Current Liabilities (Yearly) stood at $437,000 in 2020, then crashed by 93.14% to $30,000 in 2021, then tumbled by 93.33% to $2,000 in 2022, then reached $6.2 million in 2024.